Technical Articles

In the battlefield of lung cancer treatment, molecular targeted therapy is like a precise "sniper", which brings new hope to patients with its ability to kill tumor cells efficiently and selectively. In particular, targeted drugs targeting epidermal growth factor receptor (EGFR) have become an important part of non-small cell lung cancer (NSCLC) treatment.

EGFR (Epidermal Growth Factor Receptor), also known as ERBB1, is the expression product of the proto-oncogene c-erbB1 and a member of the HER family, which also includes HER2 (erbB2, NEU), HER3 (erbB3), and HER4 (erbB4). These receptors belong to the receptor tyrosine kinase (RTKs) family.